알비모판(Alvimopan) : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Alvimopan was estimated to be worth US$ 31.37 million in 2024 and is forecast to a readjusted size of US$ 42.74 million by 2031 with a CAGR of 4.6% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Alvimopan cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Alvimopan is a peripherally acting μ-opioid receptor antagonist indicated for management of postoperative ileus (POI) to accelerate gastrointestinal recovery after bowel resection. Its pharmacologic profile produces selective peripheral blockade of opioid effects in the gut while sparing central analgesia, enabling faster return of bowel function without undermining postoperative pain control. Clinical use is constrained to short-term, inpatient administration under controlled hospital protocols and stewardship programs, reflecting its profile as a specialized hospital-use prescription product. The product's development history-from small biotech discovery to collaboration and commercialization by larger pharmaceutical companies-illustrates a common industrial pathway from innovation to regulated market entry. In 2024, global Alvimopan production reached approximately 19187 units , with an average global market price of around US$ 1635 per unit.

The clinical domain targeted by alvimopan-accelerating postoperative gastrointestinal recovery-addresses a direct operational and patient-experience pain point: postoperative bowel recovery influences length of stay, complication profiles, and bed turnover. Pharmaceutical annual reports and analyst notes show that Enhanced Recovery After Surgery (ERAS) protocols and perioperative optimization are being institutionalized across hospitals, creating demand for adjunctive pharmacologic interventions. In an environment where hospital efficiency, reimbursement reform, and patient discharge experience are strategic priorities, short-term inpatient therapies that demonstrably shorten recovery and resource utilization have clear policy and commercial tailwinds. Clinical studies, integrated pathway initiatives, and hospital stewardship programs create structured adoption pathways for products like alvimopan.

Commercial scale-up faces constraints: labeled indications restrict use to short-term inpatient administration and safety communications (including warnings related to long-term use) limit broader outpatient application. These constraints necessitate hospital registration, stewardship, and education programs that raise the cost of adoption. Moreover, perioperative care improvements are multifactorial-surgical technique, anesthetic protocols, and non-pharmacologic measures can substitute for or reduce pharmaceutical demand. Global rollout must also navigate heterogeneous regulatory regimes and payer reimbursement frameworks, creating strategic uncertainty for cross-border expansion.

Hospitals and surgical teams increasingly prioritize interventions that deliver measurable outcomes and integrate seamlessly into clinical pathways. Demand is skewing toward agents that can be standardized into ERAS protocols, tracked through perioperative workflows, and evaluated via real-world evidence. Large hospital systems, academic medical centers, and high-volume surgical specialty centers are the primary adopters because they can scale clinical evidence, realize quality metric improvements, and monetize bed-utilization gains. Given safety and regulatory constraints, expansion into outpatient or low-acuity settings is limited; adoption depends on organized clinical integration and institutional endorsement.

As a small-molecule prescription drug, alvimopan's upstream considerations encompass API synthesis routes, critical intermediates, formulation excipients, and GMP-compliant manufacturing capacity. API production is subject to environmental regulation, batch-to-batch quality demands, and traceability requirements; stable, compliant supply relationships or internal capabilities are therefore strategic assets. Leading pharma companies emphasize using CMOs, multi-sourcing key inputs, and localized stockpiles to mitigate logistics and trade risks. Regulatory focus on drug safety and supply continuity has driven upstream investments-raising costs and entry barriers but strengthening value-chain resilience

This report aims to provide a comprehensive presentation of the global market for Alvimopan, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Alvimopan by region & country, by Type, and by Application.

The Alvimopan market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alvimopan.

Market Segmentation

By Company

• Merck
• Teva Pharmaceutical
• Endo International
• Hikma Pharmaceuticals

Segment by Type

• Brand Drug
• Generic Drug

Segment by Application

• Hsopital
• Retail Pharmacy

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Alvimopan manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Alvimopan in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Alvimopan in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Alvimopan Product Introduction
• 1.2 Global Alvimopan Market Size Forecast
  • 1.2.1 Global Alvimopan Sales Value (2020-2031)
  • 1.2.2 Global Alvimopan Sales Volume (2020-2031)
  • 1.2.3 Global Alvimopan Sales Price (2020-2031)
• 1.3 Alvimopan Market Trends & Drivers
  • 1.3.1 Alvimopan Industry Trends
  • 1.3.2 Alvimopan Market Drivers & Opportunity
  • 1.3.3 Alvimopan Market Challenges
  • 1.3.4 Alvimopan Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Alvimopan Players Revenue Ranking (2024)
• 2.2 Global Alvimopan Revenue by Company (2020-2025)
• 2.3 Global Alvimopan Players Sales Volume Ranking (2024)
• 2.4 Global Alvimopan Sales Volume by Company Players (2020-2025)
• 2.5 Global Alvimopan Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Alvimopan Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Alvimopan Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Alvimopan
• 2.9 Alvimopan Market Competitive Analysis
  • 2.9.1 Alvimopan Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Alvimopan Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alvimopan as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Brand Drug
  • 3.1.2 Generic Drug
• 3.2 Global Alvimopan Sales Value by Type
  • 3.2.1 Global Alvimopan Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Alvimopan Sales Value, by Type (2020-2031)
  • 3.2.3 Global Alvimopan Sales Value, by Type (%) (2020-2031)
• 3.3 Global Alvimopan Sales Volume by Type
  • 3.3.1 Global Alvimopan Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Alvimopan Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Alvimopan Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Alvimopan Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Hsopital
  • 4.1.2 Retail Pharmacy
• 4.2 Global Alvimopan Sales Value by Application
  • 4.2.1 Global Alvimopan Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Alvimopan Sales Value, by Application (2020-2031)
  • 4.2.3 Global Alvimopan Sales Value, by Application (%) (2020-2031)
• 4.3 Global Alvimopan Sales Volume by Application
  • 4.3.1 Global Alvimopan Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Alvimopan Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Alvimopan Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Alvimopan Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Alvimopan Sales Value by Region
  • 5.1.1 Global Alvimopan Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Alvimopan Sales Value by Region (2020-2025)
  • 5.1.3 Global Alvimopan Sales Value by Region (2026-2031)
  • 5.1.4 Global Alvimopan Sales Value by Region (%), (2020-2031)
• 5.2 Global Alvimopan Sales Volume by Region
  • 5.2.1 Global Alvimopan Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Alvimopan Sales Volume by Region (2020-2025)
  • 5.2.3 Global Alvimopan Sales Volume by Region (2026-2031)
  • 5.2.4 Global Alvimopan Sales Volume by Region (%), (2020-2031)
• 5.3 Global Alvimopan Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Alvimopan Sales Value, 2020-2031
  • 5.4.2 North America Alvimopan Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Alvimopan Sales Value, 2020-2031
  • 5.5.2 Europe Alvimopan Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Alvimopan Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Alvimopan Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Alvimopan Sales Value, 2020-2031
  • 5.7.2 South America Alvimopan Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Alvimopan Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Alvimopan Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Alvimopan Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Alvimopan Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Alvimopan Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Alvimopan Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Alvimopan Sales Value, 2020-2031
  • 6.3.2 United States Alvimopan Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Alvimopan Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Alvimopan Sales Value, 2020-2031
  • 6.4.2 Europe Alvimopan Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Alvimopan Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Alvimopan Sales Value, 2020-2031
  • 6.5.2 China Alvimopan Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Alvimopan Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Alvimopan Sales Value, 2020-2031
  • 6.6.2 Japan Alvimopan Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Alvimopan Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Alvimopan Sales Value, 2020-2031
  • 6.7.2 South Korea Alvimopan Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Alvimopan Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Alvimopan Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Alvimopan Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Alvimopan Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Alvimopan Sales Value, 2020-2031
  • 6.9.2 India Alvimopan Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Alvimopan Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Merck
  • 7.1.1 Merck Company Information
  • 7.1.2 Merck Introduction and Business Overview
  • 7.1.3 Merck Alvimopan Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Merck Alvimopan Product Offerings
  • 7.1.5 Merck Recent Development
• 7.2 Teva Pharmaceutical
  • 7.2.1 Teva Pharmaceutical Company Information
  • 7.2.2 Teva Pharmaceutical Introduction and Business Overview
  • 7.2.3 Teva Pharmaceutical Alvimopan Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Teva Pharmaceutical Alvimopan Product Offerings
  • 7.2.5 Teva Pharmaceutical Recent Development
• 7.3 Endo International
  • 7.3.1 Endo International Company Information
  • 7.3.2 Endo International Introduction and Business Overview
  • 7.3.3 Endo International Alvimopan Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Endo International Alvimopan Product Offerings
  • 7.3.5 Endo International Recent Development
• 7.4 Hikma Pharmaceuticals
  • 7.4.1 Hikma Pharmaceuticals Company Information
  • 7.4.2 Hikma Pharmaceuticals Introduction and Business Overview
  • 7.4.3 Hikma Pharmaceuticals Alvimopan Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Hikma Pharmaceuticals Alvimopan Product Offerings
  • 7.4.5 Hikma Pharmaceuticals Recent Development

8 Industry Chain Analysis

• 8.1 Alvimopan Industrial Chain
• 8.2 Alvimopan Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Alvimopan Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Alvimopan Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer